



MEN

FIRST CANCER SITE
HEAD AND NECK

HEAD AND NECK
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

TESTA E COLLO
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	42368		45284		45284		42368		32693		14083		5593		42368	45284
Person-years ▶	186565		193835		7270		31178		84644		46742		24001		186565	193835
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND HEAD AND NECK	5513	1.62	6262	1.78	749	6.62	659	1.35	2524	1.75	1481	1.61	849	1.51	11.28	14.14
HEAD AND NECK	480	2.96	719	4.28	239	38.95	76	2.88	234	3.21	117	2.84	53	2.46	1.70	2.84
ORAL CAVITY	221	5.86	284	7.26	63	44.49	39	6.41	102	6.05	52	5.39	28	5.50	0.98	1.26
PHARYNX	155	4.42	172	4.73	17	12.65	22	3.81	74	4.65	39	4.41	20	4.44	0.64	0.70
LARYNX	104	1.16	263	2.84	159	47.08	15	1.04	58	1.45	26	1.14	5	0.42	0.08	0.88
OESOPHAGUS	333	8.33	477	11.52	144	99.94	48	7.77	161	9.18	96	9.23	28	4.78	1.57	2.25
STOMACH	295	1.38	309	1.40	14	1.85	30	0.93	134	1.46	70	1.24	61	1.85	0.44	0.45
COLON RECTUM	510	1.06	527	1.06	17	1.08	55	0.81	228	1.13	151	1.16	76	0.94	0.16	0.16
COLON	338	1.03	347	1.03	9	0.85	36	0.79	144	1.06	108	1.21	50	0.89	0.06	0.05
RECTUM	172	1.13	180	1.14	8	1.55	19	0.85	84	1.29	43	1.05	26	1.06	0.10	0.11
LIVER	231	1.60	258	1.72	27	5.55	34	1.62	105	1.70	59	1.52	33	1.42	0.46	0.56
GALLBLADDER	39	1.07	40	1.07	1	0.84	3	0.58	15	0.99	13	1.32	8	1.29	0.01	0.01
PANCREAS	116	1.22	119	1.21	3	0.95	20	1.47	50	1.25	26	1.01	20	1.27	0.11	0.11
LUNG	2065	3.20	2420	3.63	355	15.84	245	2.54	997	3.59	543	3.19	280	2.80	7.61	9.04
SKIN MELANOMA	41	0.82	42	0.81	1	0.60	6	0.83	10	0.47	15	1.11	10	1.23	-0.05	-0.05
MESOTHELIOMA	11	0.58	12	0.61	1	1.64	0	0.00	7	0.88	2	0.39	2	0.62	-0.04	-0.04
KAPOSI SARCOMA	7	0.96	8	1.06	1	3.94	1	0.92	4	1.28	1	0.52	1	0.87	0.00	0.00
SOFT TISSUE	6	0.49	6	0.48	0	0.00	0	0.00	3	0.58	2	0.62	1	0.52	-0.03	-0.03
BONE	3	0.92	4	1.18	1	8.18	0	0.00	3	2.08	0	0.00	0	0.00	0.00	0.00
BREAST	6	0.80	6	0.77	0	0.00	1	0.91	4	1.25	0	0.00	1	0.82	-0.01	-0.01
PROSTATE	582	0.86	602	0.87	20	0.98	57	0.65	236	0.86	175	0.93	114	0.93	-0.50	-0.48
TESTIS	5	1.23	6	1.41	1	5.65	1	1.33	4	2.07	0	0.00	0	0.00	0.00	0.01
KIDNEY AND RENAL PELVIS	124	1.09	142	1.21	18	4.72	19	1.15	49	1.01	31	1.02	25	1.39	0.06	0.13
BLADDER AND URINARY TRACT	627	1.59	662	1.63	35	2.65	69	1.22	281	1.69	179	1.69	98	1.53	1.25	1.32
URINARY BLADDER	610	1.62	642	1.65	32	2.53	68	1.25	277	1.74	168	1.66	97	1.58	1.25	1.30
URINARY TRACT	17	1.01	20	1.15	3	5.41	1	0.42	4	0.57	11	2.42	1	0.35	0.00	0.01
BRAIN AND CENTRAL NERVOUS SYSTEM	33	0.79	34	0.78	1	0.67	1	0.16	15	0.82	7	0.64	10	1.60	-0.05	-0.05
THYROID	26	1.58	79	4.64	53	91.72	13	5.18	10	1.39	1	0.23	2	0.83	0.05	0.32
HODGKIN LYMPHOMA	6	0.81	8	1.04	2	6.85	0	0.00	6	1.79	0	0.00	0	0.00	-0.01	0.00
NON-HODGKIN LYMPHOMA	125	1.24	139	1.33	14	4.11	16	1.09	57	1.32	32	1.19	20	1.24	0.13	0.18
MYELOMA	32	0.70	33	0.70	1	0.65	5	0.76	11	0.57	11	0.89	5	0.66	-0.07	-0.07
LEUKAEMIAS	94	1.19	102	1.25	8	2.96	14	1.21	36	1.07	25	1.18	19	1.50	0.08	0.10
LYMPHOID LEUKAEMIAS	24	0.62	32	0.80	8	6.01	5	0.88	6	0.36	9	0.88	4	0.67	-0.08	-0.04
MYELOID LEUKAEMIAS	64	1.82	64	1.76	0	0.00	9	1.78	25	1.69	16	1.69	14	2.39	0.15	0.14
OTHER LEUKAEMIAS	6	1.13	6	1.09	0	0.00	0	0.00	5	2.19	0	0.00	1	1.23	0.00	0.00
OTHER AND ILL DEFINED SITES	196	1.10	227	1.23	31	5.17	21	0.82	98	1.31	42	0.88	35	1.18	0.10	0.22

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN FIRST CANCER SITE
HEAD AND NECK

HEAD AND NECK
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

TESTA E COLLO
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
SECOND CANCER SITE	0	SIR	0	SIR	0	SIR	0	SIR	0	SIR	0	SIR	0	SIR	EAR	EAR
ALL SITES, BUT SKIN AND HEAD AND NECK	628	1.58	718	1.73	90	5.69	85	1.31	306	1.75	155	1.51	82	1.46	6.11	7.77
HEAD AND NECK	77	14.70	104	19.10	27	129.34	10	11.59	33	14.25	26	19.44	8	11.08	1.91	2.52
ORAL CAVITY	46	16.55	58	20.08	12	109.09	5	11.12	19	15.70	18	25.09	4	9.96	1.15	1.41
PHARYNX	18	15.37	18	14.77	0	0.00	2	10.04	8	15.11	6	20.41	2	13.45	0.45	0.43
LARYNX	13	10.10	28	20.92	15	293.57	3	14.03	6	10.42	2	6.13	2	11.66	0.31	0.68
OESOPHAGUS	38	19.44	48	23.61	10	126.87	1	3.14	23	27.16	12	23.81	2	7.00	0.96	1.18
STOMACH	27	1.16	30	1.24	3	3.06	4	1.03	11	1.09	8	1.35	4	1.23	0.10	0.15
COLON RECTUM	74	1.21	78	1.22	4	1.65	12	1.21	31	1.16	19	1.19	12	1.34	0.34	0.36
COLON	43	0.98	46	1.00	3	1.73	8	1.13	14	0.73	14	1.22	7	1.08	-0.03	0.00
RECTUM	31	1.79	32	1.78	1	1.44	4	1.41	17	2.24	5	1.12	5	2.05	0.36	0.36
LIVER	14	1.34	14	1.29	0	0.00	1	0.60	6	1.33	7	2.58	0	0.00	0.09	0.08
GALLBLADDER	5	0.60	5	0.57	0	0.00	1	0.73	2	0.55	2	0.93	0	0.00	-0.09	-0.09
PANCREAS	14	0.88	14	0.85	0	0.00	2	0.80	6	0.89	3	0.72	3	1.23	-0.05	-0.06
LUNG	165	6.51	192	7.30	27	28.03	15	3.76	91	8.29	38	5.74	21	5.58	3.72	4.24
SKIN MELANOMA	4	0.53	6	0.77	2	6.90	1	0.82	2	0.60	1	0.52	0	0.00	-0.09	-0.05
MESOTHELIOMA	1	0.92	1	0.89	0	0.00	0	0.00	1	2.13	0	0.00	0	0.00	0.00	0.00
KAPOSI SARCOMA	2	3.83	2	3.67	0	0.00	0	0.00	2	8.90	0	0.00	0	0.00	0.04	0.04
SOFT TISSUE	7	4.19	8	4.60	1	15.22	1	3.67	5	6.79	0	0.00	1	4.26	0.14	0.16
BONE	2	4.43	2	4.25	0	0.00	1	13.15	0	0.00	0	0.00	1	16.70	0.04	0.04
BREAST	125	1.20	145	1.33	20	4.83	23	1.33	56	1.20	36	1.36	10	0.72	0.55	0.93
CERVIX UTERI	13	2.40	14	2.48	1	4.29	1	1.03	8	3.20	2	1.53	2	3.18	0.20	0.21
CORPUS UTERI	20	1.06	20	1.02	0	0.00	3	0.96	5	0.59	5	1.04	7	2.83	0.03	0.01
OVARY	8	0.63	9	0.68	1	1.95	1	0.47	2	0.35	1	0.31	4	2.36	-0.13	-0.11
KIDNEY AND RENAL PELVIS	10	1.04	12	1.20	2	5.45	0	0.00	6	1.43	3	1.19	1	0.71	0.01	0.05
BLADDER AND URINARY TRACT	17	1.13	17	1.09	0	0.00	2	0.83	10	1.54	4	1.02	1	0.45	0.05	0.04
URINARY BLADDER	17	1.22	17	1.17	0	0.00	2	0.90	10	1.66	4	1.10	1	0.49	0.08	0.06
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
BRAIN AND CENTRAL NERVOUS SYSTEM	3	0.52	4	0.66	1	4.40	1	1.06	1	0.39	0	0.00	1	1.24	-0.07	-0.05
THYROID	12	1.59	21	2.68	9	30.80	6	4.80	3	0.88	1	0.52	2	2.07	0.12	0.34
HODGKIN LYMPHOMA	1	1.01	1	0.97	0	0.00	0	0.00	1	2.22	0	0.00	0	0.00	0.00	0.00
NON-HODGKIN LYMPHOMA	20	1.34	23	1.48	3	5.17	4	1.66	11	1.68	4	1.04	1	0.47	0.14	0.19
MYELOMA	6	0.87	6	0.84	0	0.00	1	0.90	2	0.67	1	0.56	2	2.02	-0.02	-0.03
LEUKAEMIAS	12	1.23	12	1.19	0	0.00	0	0.00	5	1.18	5	1.99	2	1.44	0.06	0.05
LYMPHOID LEUKAEMIAS	4	0.93	4	0.89	0	0.00	0	0.00	1	0.53	3	2.71	0	0.00	-0.01	-0.01
MYELOID LEUKAEMIAS	7	1.52	7	1.46	0	0.00	0	0.00	3	1.50	2	1.67	2	2.98	0.06	0.06
OTHER LEUKAEMIAS	1	1.25	1	1.20	0	0.00	0	0.00	1	2.90	0	0.00	0	0.00	0.01	0.00
OTHER AND ILL DEFINED SITES	28	0.97	34	1.13	6	5.16	4	0.86	16	1.29	3	0.40	5	1.16	-0.02	0.10

Decrease/Difetto / Increase/Eccesso O Observed cases / Casi osservati SIR Standardized Incidence Ratio / Rapporto standardizzato di incidenza EAR Excess Absolute Risk / Eccesso assoluto di rischio